Clínica Médica

M-A | Prevalência e métodos de avaliação da disfagia orofaríngea em idosos.

18 Mai, 2022 | 15:54h

Prevalence and Methods for Assessment of Oropharyngeal Dysphagia in Older Adults: A Systematic Review and Meta-Analysis – Journal of Clinical Medicine

---

Estudo randomizado | Efeito da posição prona na entubação endotraqueal de pacientes com COVID-19 e insuficiência respiratória aguda.

17 Mai, 2022 | 12:13h

Effect of Awake Prone Positioning on Endotracheal Intubation in Patients With COVID-19 and Acute Respiratory Failure: A Randomized Clinical Trial – JAMA

Conteúdos relacionados:

Assessment of Awake Prone Positioning in Hospitalized Adults With COVID-19: A Nonrandomized Controlled Trial – JAMA Internal Medicine

Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis – The Lancet Respiratory Medicine

Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE) – The BMJ

RCT: Prone positioning of patients with moderate hypoxia due to COVID-19 – medRxiv

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial – The Lancet Respiratory Medicine

Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19: the PROFLO multicenter randomized clinical trial – Critical Care

Prone Positioning of Nonintubated Patients With Coronavirus Disease 2019—A Systematic Review and Meta-Analysis – Critical Care Medicine

 

Comentário no Twitter

In this trial, in patients with acute hypoxemic respiratory failure from #COVID19, prone positioning, compared with usual care without prone positioning, did not significantly reduce endotracheal intubation at 30 days. https://t.co/1RyYRtcrYj

— JAMA (@JAMA_current) May 15, 2022

 

---

Estudo randomizado | Inalador de resgate com dose fixa combinada de albuterol-budesonida para asma.

17 Mai, 2022 | 12:10h

Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma – New England Journal of Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

The risk of severe asthma exacerbation was significantly lower with as-needed use of a fixed-dose combination of 180 μg of albuterol and 160 μg of budesonide than with albuterol alone. #ATS2022 https://t.co/MRGaUaGVwj pic.twitter.com/6BZX9Q6WxX

— NEJM (@NEJM) May 15, 2022

 

---

Estudo de um inibidor de fosfodiesterase 4B na fibrose pulmonar idiopática.

17 Mai, 2022 | 12:09h

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis – New England Journal of Medicine (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

https://twitter.com/NEJM/status/1525878684380430343

 

---

Estudo randomizado | Comparação de antibioticoterapia por 8 vs. 15 dias para pneumonia por Pseudomonas aeruginosa associada a ventilador mecânico em adultos.

17 Mai, 2022 | 12:07h

Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia in adults: a randomized, controlled, open-label trial – Intensive Care Medicine (artigo gratuito aqui)

 

Comentário no Twitter

🧫 8 vs 15 days ABT for Pseudomonas aeruginosa VAP in adults, iDIAPASON RCT: no differences in composite or separate outcomes (90-day mortality/VAP recurrence) between short & long duration treatment.
📢 @yourICM ground-breaking release #LIVES40 #FOAMcc
🖇 https://t.co/LfoUWxCkkl pic.twitter.com/XaWkQ5R6wT

— Intensive Care Medicine (@yourICM) May 13, 2022

 

---

Posicionamento científico ESC | Cuidado integrado para melhorar o tratamento do AVC e da doença cardíaca associada.

17 Mai, 2022 | 12:06h

Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke – European Heart Journal

 

Comentário no Twitter

Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Strokehttps://t.co/L7dPxM6dZx#EHJ #stroke @escardio @ESC_Journals #CardioTwitter pic.twitter.com/MB6mIqzdui

— EHJ Editor-in-Chief (@ehj_ed) May 14, 2022

Sob licença de https://creativecommons.org/licenses/by-nc/4.0/

---

Diretrizes europeias para tratamento de sintomas de trato urinário inferior não neurogênico em mulheres.

17 Mai, 2022 | 11:58h

European Association of Urology Guidelines on the Management of Female Non-neurogenic Lower Urinary Tract Symptoms – European Association of Urology

---

Pontos a se considerar no EULAR 2022 para cuidado remoto nas doenças reumáticas e musculoesqueléticas.

17 Mai, 2022 | 11:56h

2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases – Annals of Rheumatic Diseases

 

Comentário no Twitter

2022 #EULAR points to consider for remote care in #rheumatic and #musculoskeletal diseaseshttps://t.co/oB0Fo0wzoM pic.twitter.com/LS95rSvCmh

— ARD & RMD Open (@ARD_BMJ) April 27, 2022

 

---

Mortalidade em pessoas com esquizofrenia: revisão sistemática e metanálise de risco relativo e fatores agravantes e atenuantes.

17 Mai, 2022 | 11:52h

Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors – World Psychiatry

---

Estudo randomizado | Terapia com dorzagliatina adicionada à metformina em pacientes com diabetes tipo 2.

17 Mai, 2022 | 11:51h

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial – Nature Medicine

Estudo relacionado: Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial – Nature Medicine

Comentário: DAWN: Support for dorzagliatin–metformin combination therapy in type 2 diabetes – medwireNews

 

Comentário no Twitter

The DAWN study is a #phase3 clinical trial that demonstrates effective #glycemic control of #dorzagliatin as an add-on therapy to #metfomin in patients with type 2 #diabetes. #T2D #NMEDClinicalhttps://t.co/9bHWQNvNTJ

— Nature Medicine (@NatureMedicine) May 12, 2022

 

---